Abacavir sulfate, lamivudine and zidovudine (DrugBank: Zidovudine, Lamivudine, Abacavir, Sulfate)
3 diseases告示番号 | 疾患名(ページ内リンク) | 臨床試験数 |
---|---|---|
135 | アイカルディ症候群 | 0 |
265 | 脂肪萎縮症 | 1 |
325 | 遺伝性自己炎症疾患 | 0 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT00021463 (ClinicalTrials.gov) | April 2001 | 14/7/2001 | Changing to Nonprotease Inhibitor Treatment to Improve Side Effects | Phase II, Randomized, Open-Label Study of Switching to Protease Inhibitor-Sparing Regimens for Improvement of Metabolic Abnormalities | HIV Infections;Lipodystrophy | Drug: Abacavir sulfate, Lamivudine and Zidovudine;Drug: Abacavir sulfate;Drug: Efavirenz;Drug: Nevirapine | National Institute of Allergy and Infectious Diseases (NIAID) | NULL | Completed | 13 Years | N/A | Both | 342 | Phase 2 | United States |